Yan-Mei Zhang1, Chao Cao, Kun Liang. 1. Department of Internal Medicine, the Second Hospital of Anhui Medical University, 678 Furong Road, Hefei 230601, China. zhangym19840130@126.com <zhangym19840130@126.com>
Abstract
BACKGROUND: Numerous studies have investigated the risk of cancer associated with the polymorphism of epidermal growth factor (EGF) 61A>G, but the results have been inconsistent. We performed this meta-analysis to drive a more precise estimation of association between this polymorphism and risk of cancer. METHODS: Electronic searches of PubMed and EMBASE were conducted to select studies. Case-control studies containing available genotype frequencies of EGF 61A>G were chose, and Odds ratio (OR) with 95% confidence interval (CI) was used to assess the strength of this association. RESULTS: 23 case-control studies including 5578 cases and 7306 controls were identified. This meta-analysis showed significant effect of EGF 61A>G on cancer risk (GG vs. AA: OR=1.34, 95%CI=1.05-1.72; GG vs. GA+AA: OR=1.23, 95%CI=1.03-1.47; GG+GA vs. AA: OR=1.18, 95%CI=1.02-1.38). In subgroup analysis, significant increased risk was found in gastric cancer and glioma in additive model (OR=1.54, 95%CI=1.13-2.12; OR=1.69, 95%CI=1.21-2.37) and in recessive model (OR=1.29, 95%CI=1.10-1.52; OR=1.54, 95%CI=1.16-2.04). CONCLUSION: This meta-analysis suggested that the EGF 61G allele is a risk factor of cancer, especially for gastric cancer and glioma.
BACKGROUND: Numerous studies have investigated the risk of cancer associated with the polymorphism of epidermal growth factor (EGF) 61A>G, but the results have been inconsistent. We performed this meta-analysis to drive a more precise estimation of association between this polymorphism and risk of cancer. METHODS: Electronic searches of PubMed and EMBASE were conducted to select studies. Case-control studies containing available genotype frequencies of EGF 61A>G were chose, and Odds ratio (OR) with 95% confidence interval (CI) was used to assess the strength of this association. RESULTS: 23 case-control studies including 5578 cases and 7306 controls were identified. This meta-analysis showed significant effect of EGF 61A>G on cancer risk (GG vs. AA: OR=1.34, 95%CI=1.05-1.72; GG vs. GA+AA: OR=1.23, 95%CI=1.03-1.47; GG+GA vs. AA: OR=1.18, 95%CI=1.02-1.38). In subgroup analysis, significant increased risk was found in gastric cancer and glioma in additive model (OR=1.54, 95%CI=1.13-2.12; OR=1.69, 95%CI=1.21-2.37) and in recessive model (OR=1.29, 95%CI=1.10-1.52; OR=1.54, 95%CI=1.16-2.04). CONCLUSION: This meta-analysis suggested that the EGF 61G allele is a risk factor of cancer, especially for gastric cancer and glioma.
Authors: Ana Paula Araújo; Bruno M Costa; Ana L Pinto-Correia; Maria Fragoso; Paula Ferreira; Mário Dinis-Ribeiro; Sandra Costa; Rui M Reis; Rui Medeiros Journal: World J Gastroenterol Date: 2011-01-28 Impact factor: 5.742
Authors: Ramon Andrade de Mello; Mónica Ferreira; Sandra Costa; Bruno Marques Costa; Filipa Soares Pires; Inês Neves; Maria Inês Almeida; João Cunha; Pedro Oliveira; Venceslau Hespanhol; Rui Manuel Reis Journal: Tumour Biol Date: 2012-03-29
Authors: S Cmet; C Fabris; G Fattovich; E Falleti; D Bitetto; A Cussigh; E Fontanini; E Fornasiere; M Pirisi; P Toniutto Journal: Clin Exp Immunol Date: 2012-02 Impact factor: 4.330
Authors: Francisco das Chagas Abreu da Silveira; Bruno de Almeida Lopes; Clovis Orlando da Fonseca; Thereza Quirico-Santos; Izabel Christina Nunes de Palmer Paixão; Lidia Maria da Fonte de Amorim Journal: J Cancer Res Clin Oncol Date: 2012-04-06 Impact factor: 4.553